FoRx Therapeutics is a recently incorporated privately-held company aiming to develop first-in-class compounds for cancer treatment.
FoRx focuses on drugging key molecular targets involved in DNA replication stress, as a new approach towards the development of targeted anticancer drugs.
FoRx scientists bring more than 20 years of experience in DNA replication stress and DNA Damage Response pathways. Our team consists of scientists and advisors with extensive experience in cancer biology, cancer genomics, biochemistry, medicinal chemistry and small molecule drug discovery. FoRx is located in Basel, Switzerland, a world-leading hub of biotech and pharmaceutical industry.